<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04707872</url>
  </required_header>
  <id_info>
    <org_study_id>ATAGC06</org_study_id>
    <nct_id>NCT04707872</nct_id>
  </id_info>
  <brief_title>Trifecta-Heart cfDNA-MMDx Study</brief_title>
  <official_title>Trifecta-Heart cfDNA-MMDX Study: Comparing the DD-cfDNA Test to MMDx Microarray Test and Central HLA Antibody Test</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Natera, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>One Lambda</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alberta</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Demonstrate the relationship between DD-cfDNA levels and HLA antibodies in blood transplant&#xD;
      recipient and the Molecular Microscope® (MMDx) Diagnostic System results in indication and&#xD;
      protocol biopsies from heart transplants.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The current standard for assessment of rejection in heart transplants is an endomyocardial&#xD;
      biopsy (EMB) interpreted by histology according to ISHLT guidelines. This has considerable&#xD;
      error rates, many due to the high disagreement among pathologists in assessing lesions and&#xD;
      diagnoses. To address the unmet need for precision and accuracy, the Alberta Transplant&#xD;
      Applied Genomics Centre (ATAGC, University of Alberta) has developed a new diagnostic system&#xD;
      - the Molecular Microscope® Diagnostic System (MMDx), which uses microarrays to define the&#xD;
      global gene expression features of rejection and injury. Now a new screening test is being&#xD;
      introduced: the monitoring of donor-derived cell-free DNA (DD-cfDNA) released in the blood by&#xD;
      the heart during rejection. The Natera Inc DD-cfDNA Prospera® test is based on the massively&#xD;
      multiplex polymerase chain reaction that targets 13,392 single nucleotide polymorphisms and&#xD;
      targeted sequences are quantified by Next Generation Sequencing. The Prospera® test has been&#xD;
      done on kidney transplant recipients and detected &quot;active rejection&quot; and differentiated it&#xD;
      from borderline rejection and no rejection. However, Prospera® test was not examined (the&#xD;
      DD-cfDNA results) in heart transplant recipients. DD-cf-DNA test for heart transplants must&#xD;
      now be calibrated against MMDx that is based on global gene expression, the new standard for&#xD;
      biopsy interpretation. The present study will calibrate centrally measured (Natera Inc)&#xD;
      DD-cfDNA levels obtained at the time of an indication or protocol biopsy against the MMDx&#xD;
      measurements of T cell-mediated rejection (TCMR), antibody-mediated rejection (ABMR) and&#xD;
      early and late tissue injury. The present study will compare DD-cfDNA and MMDx in 300&#xD;
      prospectively collected biopsies for clinical indications and protocol, and accompanying 600&#xD;
      blood samples, to calibrate the DD-cfDNA (Natera Inc.) levels against the MMDx biopsy&#xD;
      diagnoses of TCMR, ABMR (and its stages), and acute (early) and chronic (late) injury, , as&#xD;
      well as central assessment of HLA antibody (One Lambda) in 300 blood samples, interpreted&#xD;
      centrally as donor specific antibody (DSA) based on the tissue typing results. Due to a&#xD;
      considerable interest from participation centers, we extend this study to 700 biopsies and&#xD;
      corresponding blood samples. This study is an extension of the INTERHEART ClinicalTrials.gov&#xD;
      Identifier: NCT02670408&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2021</start_date>
  <completion_date type="Anticipated">July 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Calibration of Prospera test for T cell-mediated rejection</measure>
    <time_frame>18 months</time_frame>
    <description>Set DD-cfDNA test cut-off values against the probability of T cell-mediated rejection in the biopsy as reported by MMDx. Calibration of DD-cfDNA test cut-off values against the probability of T cell-mediated rejection in the biopsy as reported by MMDx.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Calibration of Prospera test for antibody-mediated rejection</measure>
    <time_frame>18 months</time_frame>
    <description>Set DD-cfDNA test cut-off values against the probability of antibody-mediated rejection in the biopsy as reported by MMDx.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Calibration of Prospera test for heart injury</measure>
    <time_frame>18 month</time_frame>
    <description>Set DD-cfDNA test cut-off values against the probability of acute and chronic heart injury in the biopsy as reported by MMDx.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Report calibrated Prospera test results for rejection</measure>
    <time_frame>6 months</time_frame>
    <description>Obtain clinicians feedback</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Report calibrated Prospera test results for heart injury</measure>
    <time_frame>6 month</time_frame>
    <description>Obtain clinicians feedback</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine if Prospera blood test can replace heart biopsy test</measure>
    <time_frame>6 month</time_frame>
    <description>Obtain clinicians feedback</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine if Prospera blood test can replace follow up heart biopsy</measure>
    <time_frame>6 month</time_frame>
    <description>Determine whether resolution of DD-cfDNA after treatment can monitor response to therapy and avoid follow-up biopsies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of donor-specific antibody status</measure>
    <time_frame>6 months</time_frame>
    <description>Report and compare the DSA status based on centralized and local HLA antibody measurement.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Heart Transplant Rejection</condition>
  <arm_group>
    <arm_group_label>Heart transplant protocol and for cause biopsies</arm_group_label>
    <description>The study population includes patients with a functioning heart transplant undergoing a biopsy for clinical indications as standard of care, or protocol biopsies of heart in high-risk patients, or follow-up after treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>MMDx diagnostic test</intervention_name>
    <description>Microarray test of gene expression in heart biopsies</description>
    <arm_group_label>Heart transplant protocol and for cause biopsies</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Prospera</intervention_name>
    <description>Donor derived cell-free DNA in patient blood</description>
    <arm_group_label>Heart transplant protocol and for cause biopsies</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>HLA antibody</intervention_name>
    <description>Centralized measurement of HLA antibodies in patient blood</description>
    <arm_group_label>Heart transplant protocol and for cause biopsies</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      RNA isolated from patient biopsy.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study population includes patients with a functioning heart transplant undergoing a&#xD;
        biopsy for clinical indications or surveillance (protocol) biopsy.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All heart transplant recipients undergoing a biopsy for clinical indications and&#xD;
             protocol biopsies, as determined by their physician or surgeon, will be eligible to&#xD;
             enroll in the study.&#xD;
&#xD;
          -  Patients are enrolled based on standard of care biopsies, including surveillance&#xD;
             biopsies in high-risk patients, with informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients will be excluded from the study if they decline participation&#xD;
&#xD;
          -  Are unable to give informed consent.&#xD;
&#xD;
          -  Recipients of multiple organs.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip F Halloran, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Alberta Transplant Applied Genomics Center, University of Alberta</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Konrad Famulski, PhD</last_name>
    <phone>1 780 782 9463</phone>
    <email>konrad@ualberta.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Robert Polakowski, PhD</last_name>
    <phone>1 780 492 5091</phone>
    <email>polakows@ualberta.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UCLA Medical Centre</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eugene DePasquale, MD</last_name>
      <email>EDepasquale@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Martin Cadeiras, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mario Deng, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Heart Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Brandy Starks, MBA</last_name>
      <phone>310-248-7141</phone>
      <email>jon.kobashigawa@cshs.org</email>
    </contact>
    <contact_backup>
      <last_name>Kobashigawa, MD</last_name>
      <email>jon.kobashigawa@cshs.org</email>
    </contact_backup>
    <investigator>
      <last_name>Jon Kobashigawa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Annette C. and Harold C. Simmons Transplant Institute, BaylorScott&amp;White Research Institute</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aayla K Jamil, MBBS</last_name>
      <email>Aayla.Jamil@BSWHealth.org</email>
    </contact>
    <investigator>
      <last_name>Shelley Hall, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardiac Transplantation Laboratory, The Victor Chang Cardiac Research Institute</name>
      <address>
        <city>Darlinghurst</city>
        <zip>NSW 2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carmen Herrera, MD</last_name>
      <email>peter.macdonal@svha.org.au</email>
    </contact>
    <investigator>
      <last_name>Peter MacDonald, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Cardiac Surgery, Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Arezu Aliabadi, MD</last_name>
      <email>arezu.aliabadi@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Andreas Zuckerman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Johannes Gokler, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Division of Cardiology, University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2R7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Kim, MD</last_name>
      <email>dk@ualberta.ca</email>
    </contact>
    <investigator>
      <last_name>Daniel Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute for Clinical and Experimental Medicine - IKEM Videnska 1958/9</name>
      <address>
        <city>Prague</city>
        <zip>140 21</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vojtech Melenovsky, MD PhD</last_name>
      <email>vome@ikem.cz</email>
    </contact>
    <investigator>
      <last_name>Vojtech Melenovsky, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Heart Failure and Heart Transplant Unit, University of Bologna</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laura Borgese</last_name>
      <email>laura.borgese@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Luciano Potena, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Heart Failure Transplant Unit</name>
      <address>
        <city>La Coruna</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zulaika Grille Cancela</last_name>
      <email>Zulaika.grille.cancela@sergas.es</email>
    </contact>
    <investigator>
      <last_name>Maria G Crespo-Leiro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>January 11, 2021</study_first_submitted>
  <study_first_submitted_qc>January 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2021</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Donor derived cfDNA</keyword>
  <keyword>gene expression</keyword>
  <keyword>heart transplant biopsy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Only IPD data will be shared within a participating center.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

